Replimune Group (NASDAQ:REPL) spotted trading -8.94% off 52-week high price. On the other end, the stock has been noted 391.38% away from the low price over the last 52-weeks. The stock changed 2.88% to recent value of $42.16. The stock transacted 712902 shares during most recent day however it has an average volume of 473.09K shares. The company has 39.86M of outstanding shares and 35.71M shares were floated in the market.
On Oct. 19, 2020, Replimune Group (NASDAQ:REPL) released the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.
Tanya is a respected and highly accomplished pharmaceutical industry executive with greater than 20 years of experience in global drug development across a variety of therapeutic areas, including oncology, said Philip Astley-Sparke, CEO of Replimune. It is my pleasure to welcome Tanya to our board. In particular, Tanya adds deep expertise in developing and executing regulatory strategies and we look forward to her contributions as we plan to bring our leading pipeline of oncolytic immunotherapies to market.
Ms. Lewis currently serves as the Executive Vice President, Chief Regulatory Strategy and Strategic Operations at Karyopharm Therapeutics, a publicly-traded biopharmaceutical company (Nasdaq: KPTI) where she navigated the approval of XPOVIO®. Prior to joining Karyopharm, Ms. Lewis held leadership positions at several companies, including Tesaro and Millennium, where she developed approval strategies and led interactions with U.S. and European regulators for clinical trial applications, marketing applications (including ODAC presentations) and drug labeling.
Its earnings per share (EPS) expected to touch remained -15.60% for this year.
According to the most recent quarter its current ratio was 22.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 63.28% from the mean of 20 days, 69.63% from mean of 50 days SMA and performed 120.59% from mean of 200 days price. Company’s performance for the week was 70.07%, 70.00% for month and YTD performance remained 193.80%.